The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand ...

Lipella Pharmaceuticals Inc. (LIPO), a clinical-stage biotechnology company, Wednesday said that the U.S. Food and Drug ...

Mental health support is a crucial aspect that goes beyond a brand’s ethical responsibility to care for its employees. It’s ...

JHEAP's free and confidential service for employees and their household members includes one-on-one counseling, legal ...

BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Broken String Biosciences (“Broken String”), a leader in advancing gene editing safety, today opened its Catalyst Early Access Program (EAP ...

has granted approval for an Expanded Access Program (EAP) for LP-310, an oral rinse formulation designed to treat oral lichen planus (OLP). LP-310 is an innovative, localized therapy formulated to ...

Lipella Pharma receives US FDA nod for expanded access programme for LP-310, an oral rinse formulation to treat oral lichen planus: Pittsburgh Saturday, February 8, 2025, 09:00 Hr ...

PITTSBURGH - Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a biotech firm specializing in novel therapies for medical conditions lacking adequate treatments, has received FDA approval for an Expanded ...